Genetic Signatures (GSS) Q3 2026 TU earnings summary

Executive summary

• Q3 FY2026 sales reached $3 million, reflecting seasonal respiratory testing rates in Australia.

• Organisational restructuring implemented, resulting in 30 redundancies and estimated annual cost savings of $5 million from FY2027.

• Signed a ten-year supply agreement with Hvidovre Hospital in Denmark for equipment and reagents, targeting 28,000 clinical samples in year one with 3% annual growth.

• Transitioned elements of product development to contract research organisations to enhance flexibility and reduce fixed costs.

Financial highlights

• Cash and term deposits totaled $25.7 million as of 31 March 2026.

• Receipts from customers for the quarter were $3.7 million.

• Net operating cash outflow for the quarter was $3.5 million.

• Net investing cash outflow was $0.3 million, mainly for equipment investments.

• Payments to Directors, including the CEO, totaled $0.3 million for the quarter.

Outlook and guidance

• Operating in a highly competitive environment with uncertainty around the Australian flu season, which may impact Q4 FY2026 revenues.

• Focused on advancing the EasyScreen molecular diagnostic platform in established and new markets.

• Organisational restructure and strong balance sheet position the company to pursue commercial partnerships and new market opportunities.